Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis

BACKGROUND AND AIMS: Vedolizumab is an anti-α4β7 antibody approved for the treatment of ulcerative colitis [UC]. Although it is assumed that vedolizumab blocks intestinal homing of lymphocytes, its effects on different intestinal cell populations are not fully stablished. In order to establish the u...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Crohns Colitis
Autori principali: Veny, Marisol, Garrido-Trigo, Alba, Corraliza, Ana M, Masamunt, Maria C, Bassolas-Molina, Helena, Esteller, Miriam, Arroyes, Montserrat, Tristán, Eva, Fernández-Clotet, Agnès, Ordás, Ingrid, Ricart, Elena, Esteve, Maria, Panés, Julian, Salas, Azucena
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7944518/
https://ncbi.nlm.nih.gov/pubmed/32926095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjaa178
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi